| Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration … L Kabasakal, M AbuQbeitah, A Aygün, N Yeyin, M Ocak, E Demirci, ... European journal of nuclear medicine and molecular imaging 42, 1976-1983, 2015 | 209 | 2015 |
| Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging E Demirci, OE Sahin, M Ocak, B Akovali, J Nematyazar, L Kabasakal Nuclear medicine communications 37 (11), 1169-1179, 2016 | 170 | 2016 |
| Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours L Kabasakal, E Demirci, M Ocak, C Decristoforo, A Araman, Y Ozsoy, ... European journal of nuclear medicine and molecular imaging 39, 1271-1277, 2012 | 159 | 2012 |
| Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging L Kabasakal, E Demirci, M Ocak, R Akyel, J Nematyazar, A Aygun, ... Nuclear medicine communications 36 (6), 582-587, 2015 | 153 | 2015 |
| 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma E Demirci, M Ocak, L Kabasakal, C Decristoforo, Z Talat, M Halaç, ... European journal of nuclear medicine and molecular imaging 41, 1461-1462, 2014 | 142 | 2014 |
| The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer C Öbek, T Doğanca, E Demirci, M Ocak, AR Kural, A Yıldırım, U Yücetaş, ... European journal of nuclear medicine and molecular imaging 44, 1806-1812, 2017 | 130 | 2017 |
| Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? E Demirci, L Kabasakal, OE Sahin, E Akgün, MH Gültekin, T Doganca, ... Nuclear medicine communications 40 (1), 86-91, 2019 | 100 | 2019 |
| Lightweight design of an automobile hinge component using glass fiber polyamide composites T Güler, E Demirci, AR Yıldız, U Yavuz Materials Testing 60 (3), 306-310, 2018 | 96 | 2018 |
| Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry L Kabasakal, T Toklu, N Yeyin, E Demirci, M Abuqbeitah, M Ocak, ... Molecular imaging and radionuclide therapy 26 (2), 62, 2017 | 79 | 2017 |
| 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update E Demirci, L Kabasakal, T Toklu, M Ocak, OE Sahin, N Alan-Selcuk, ... Nuclear medicine communications 39 (8), 789-796, 2018 | 69 | 2018 |
| Imaging cancer-associated fibroblasts (CAFs) with FAPi PET L Gilardi, LS Airò Farulla, E Demirci, I Clerici, E Omodeo Salè, F Ceci Biomedicines 10 (3), 523, 2022 | 42 | 2022 |
| Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer M Ocak, E Demirci, L Kabasakal, A Aygun, RO Tutar, A Araman, ... Nuclear medicine communications 34 (11), 1084-1089, 2013 | 38 | 2013 |
| The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels L Kabasakal, E Demirci, J Nematyazar, R Akyel, B Razavi, M Ocak, ... Nuclear Medicine Communications 38 (2), 149-155, 2017 | 37 | 2017 |
| Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria E Demirci, R Akyel, B Caner, N Alan-Selçuk, Ş Güven-Meşe, M Ocak, ... Nuclear medicine communications 41 (8), 759-767, 2020 | 17 | 2020 |
| Preclinical Evaluation of 18F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors Demirci E, Ahmed R, Ocak M, Latoche J, Radelet A, DeBlasio N, Mason NS ... Molecular Imaging 16, 1-8, 2017 | 17* | 2017 |
| Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results E Demirci, M Ocak, L Kabasakal, A Araman, Y Ozsoy, B Kanmaz Nuclear Medicine Communications 34 (8), 727-732, 2013 | 17 | 2013 |
| Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor M Ocak, T Toklu, E Demirci, N Selçuk, L Kabasakal European Journal of Nuclear Medicine and Molecular Imaging 47 (11), 2711-2712, 2020 | 16 | 2020 |
| ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCAN E Demirci, T Toklu, N Yeyin, M Ocak, N Alan-Selcuk, A Araman, ... Radiation protection dosimetry 182 (4), 518-524, 2018 | 15 | 2018 |
| The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results K Sonmezoglu, B Vatankulu, T Elverdi, R Akyel, ME Erkan, M Halac, ... Nuclear medicine communications 38 (1), 76-83, 2017 | 14 | 2017 |
| Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme MJ Oborski, E Demirci, CM Laymon, FS Lieberman, JM Mountz Clinical Nuclear Medicine 39 (10), e431-e432, 2014 | 12 | 2014 |
Meltem OcakRadiopharmacy Specialist at MITC, Columbia,MO and Prof.Dr. at Istanbul University,TRVerified email at missouri.edu
